6-fluoro-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 6-fluoro-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-ol
• 英文别名: 6-fluoro-4,4-dimethyl-2,3-dihydro-1H-naphthalen-1-ol
• 化学式: C₁₂H₁₅FO
• 分子量: 194.249
• InChiKey: CEICFIYRZVRYQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5,5-二甲基-二氢-呋喃-2-酮 、 氟苯 在 aluminum (III) chloride 、 甲醇 、 sodium tetrahydroborate 作用下， 反应 2.5h， 以0.19 g的产率得到6-fluoro-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-ol
  参考文献：
  名称：

  NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVE

  摘要：

  本发明旨在提供一种具有TrkA抑制作用的化合物，其药学上可接受的盐或其溶剂合物，以及含有其作为活性成分的药物组合物，特别用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏疾病、皮肤疾病、神经退行性疾病、传染病、干燥综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）的预防和/或治疗剂。具体地，本发明提供一种化合物或其光学异构体，其药学上可接受的盐、其溶剂合物或类似物，该化合物由式（I）表示：

  公开号：

  US20190023657A1

文献信息

• [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2014078454A1

  公开（公告）日：2014-05-22

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  公式I的化合物：或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药，其中环A、环C和X如本文定义，是TrkA激酶的抑制剂，可用于治疗可以用TrkA激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
• NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES
  申请人：Mochida Pharmaceutical Co., Ltd.

  公开号：EP3617195A1

  公开（公告）日：2020-03-04

  The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

  本发明的目的是提供一种具有TrkA抑制作用的化合物、其药学上可接受的盐或其溶液剂、含有其作为活性成分的药物组合物，以及用于医疗用途的预防和/或治疗剂，特别是用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏性疾病、皮肤病、神经退行性疾病、传染性疾病、Sjogren综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）。具体而言，本发明提供了一种由式（I）表示的化合物或其光学异构体、其药学上可接受的盐、其溶液或类似物：
• Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
  申请人：Array BioPharma Inc.

  公开号：US10351575B2

  公开（公告）日：2019-07-16

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.

  式 I 的化合物或其立体异构体、同系物或药学上可接受的盐、溶液剂或原药，其中环 A、环 C 和 X 如本文所定义，是 TrkA 激酶的抑制剂，可用于治疗可使用 TrkA 激酶抑制剂治疗的疾病，如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染性疾病、Sjogren 综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎和盆腔疼痛综合征。
• Tetrahydronaphthyl urea derivative
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US10399945B2

  公开（公告）日：2019-09-03

  The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like). Specifically, the present invention provides a compound or an optical isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or the like, the compound represented by formula (I):

  本发明的目的是提供一种具有TrkA抑制作用的化合物、其药学上可接受的盐或其溶液剂、含有其作为活性成分的药物组合物，以及用于医疗用途的预防和/或治疗剂，特别是用于TrkA参与的疾病（疼痛、癌症、炎症/炎症性疾病、过敏性疾病、皮肤病、神经退行性疾病、传染性疾病、Sjogren综合征、子宫内膜异位症、肾脏疾病、骨质疏松症等）。具体而言，本发明提供了一种由式（I）表示的化合物或其光学异构体、其药学上可接受的盐、其溶液或类似物：
• Intermediate compound of novel tetrahydronaphthyl urea derivative
  申请人：MOCHIDA PHARMACEUTICAL CO., LTD.

  公开号：US10927079B2

  公开（公告）日：2021-02-23

  An intermediate compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is disclosed wherein the intermediate compound is represented by formula (AM-2-RR)⋅(D-TA): in which p represents an integer of 0 to 4; R1 each independently represent a halogen atom, a cyano group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a hydroxy C1-6 alkyl group, a cyanated C1-6 alkyl group, a halogenated C1-6 alkoxy group, a C1-6 alkoxy C1-6 alkyl group, a mono-/di-C2-7 alkanoyl amino group, a carboxamide group, or a C1-6 alkoxy carbonyl group; and R2a and R2b each independently represent a C1-6 alkyl group.

  公开了一种中间体化合物、其药学上可接受的盐或其溶液，其中中间体化合物由式 (AM-2-RR)⋅(D-TA) 表示： 其中 p 代表 0 至 4 的整数；R1 各自独立地代表卤素原子、氰基、C1-6 烷基、卤代 C1-6 烷基、羟基 C1-6 烷基、氰代 C1-6 烷基、卤代 C1-6 烷氧基、C1-6 烷氧基 C1-6 烷基、单-/二-C2-7 烷酰基氨基、羧酰胺基或 C1-6 烷氧基羰基；以及 R2a 和 R2b 各自独立地代表 C1-6 烷基。